Lei Shi

Years Active: 2018-2023
Publications (10 Years): 7

China Pharmaceutical University

Nanjing University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

China Pharmaceutical University Jul 01 2017

China

Associate Professor :: Department of Medicinal Chemistry

China Pharmaceutical University Jul 01 2010 - Jul 01 2016

China

Assitant Professor :: Department of Medicinal Chemistry

Education History

Nanjing University Sep 01 2005 - Jun 20 2010

China

PHD :: School of Life Sciences

Nanjing University Sep 01 2001 - Jun 24 2005

China

BSC :: School of Life Sciences

Publications

Zhen-Ling Liu, Huan-Huan Chen, Li-Li Zheng, Li-Ping Sun, Lei Shi
Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal transduction and targeted therapy 8 (1) (2023)
Zhen-Ling Liu, Huan-Huan Chen, Li-Li Zheng, Li-Ping Sun, Lei Shi
Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal transduction and targeted therapy 8 (1) (2023)
Zhen-Ling Liu, Huan-Huan Chen, Li-Li Zheng, Li-Ping Sun, Lei Shi
Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal transduction and targeted therapy 8 (1) (2023)
Zhen-Ling Liu, Huan-Huan Chen, Li-Li Zheng, Li-Ping Sun, Lei Shi
Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal transduction and targeted therapy 8 (1) (2023)
Natsumi Tsuboyama, Ru Wang, Aileen Patricia Szczepanski, Huanhuan Chen, Zibo Zhao, Lei Shi, Lu Wang
Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer. Oncogene 41 (15) (2022)
Huanhuan Chen, Zhenling Liu, Lili Zheng, Rongrong Wang, Lei Shi
BET inhibitors: an updated patent review (2018-2021). Expert opinion on therapeutic patents 32 (9) (2022)
Qing-Wen Zhang, Zi-Dan Ye, Lei Shi
c-Met kinase inhibitors: an update patent review (2014-2017). Expert opinion on therapeutic patents 29 (1) (2018)

Lei Shi.css-eqlu8i{font-size:small;padding-left:4px;}